Ken Griffin Sera Prognostics, Inc. Transaction History

Citadel Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$5.6 - $11.69 $611,279 - $1.28 Million	109,157 New	109,157 $646,000
Q2 2023 Aug 14, 2023	SELL	$3.0 - $3.98 $25,548 - $33,893	-8,516 Reduced 41.33%	12,087 $39,000
Q1 2023 May 15, 2023	BUY	$1.19 - $4.25 $24,517 - $87,562	20,603 New	20,603 $78,000
Q3 2022 Nov 14, 2022	BUY	$1.55 - $2.71 $19,464 - $34,032	12,558 New	12,558 $20,000

20.3M

120K

Ticker SERA
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 29,596,900
Market Cap $237M
Description
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.